Picoplatin

Picoplatin is a platinum-based antineoplastic agent in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid tumors.[1]

Picoplatin
Names
IUPAC name
azane; 2-methylpyridine; platinum(2+); dichloride
Identifiers
3D model (JSmol)
ChemSpider
ECHA InfoCard 100.205.233
UNII
  • InChI=1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2 ☒N
    Key: IIMIOEBMYPRQGU-UHFFFAOYSA-L ☒N
  • InChI=1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2
    Key: IIMIOEBMYPRQGU-NUQVWONBAG
  • ionic form: Cc1ccccn1.N.[Cl-].[Cl-].[Pt+2]
  • coordination form: Cl[Pt-2](Cl)([NH3+])[n+]1ccccc1C
Properties
C6H10Cl2N2Pt
Molar mass 376.14 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)
Infobox references

In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.[2] However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced small cell lung cancer.[3] Hopes are now pinned on its use for metastatic colorectal cancer.[4]

References
  1. Wheate, Nial J. (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials" (PDF). Dalton Transactions. 39 (35): 8113–8127. doi:10.1039/C0DT00292E. hdl:2123/14271. PMID 20593091.
  2. Picoplatin Clinical Results, Poniard Pharmaceuticals
  3. Poniard shares crash on Phase III picoplatin failure, fiercebiotech.com, November 16, 2009
  4. http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.